Physician profile
John David Chase
NPI 1528065547
$1,283.84
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $382 · 2021: $388 · 2022: $264.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $857.27 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $97.84 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $94.72 | 2021 | |
| Genzyme Corporation | $59.56 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $35.69 | 2019-2020 | |
| Abbvie INC. | $25.63 | 2021 | |
| Amgen INC. | $23.87 | 2019-2020 | |
| Lilly USA, LLC | $15.05 | 2020 | |
| Mdd US Operations, LLC | $14.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.49 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.84 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.